|[November 28, 2012]
Rexahn Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrant
ROCKVILLE, Md. --(Business Wire)--
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) today announced that
it intends to offer shares of its common stock and warrants to purchase
common stock in an underwritten public offering. The shares of common
stock and warrants are being offered as units. The offering is subject
to market and other conditions, and there can be no assurances as to
whether or when the offering may be completed, or as to the actual size
or terms of the offering. Rexahn also expects to grant the underwriters
a 45-day option to purchase additional shares of common stock and
warrants to cover over-allotments, if any.
Burrill LLC and Maxim Group LLC are acting as joint book-running mangers
for the offering.
The securities described above are being offered by Rexahn pursuant to a
shelf registration statement that was previously filed with and declared
effective by the Securities and Exchange Commission (SEC (News - Alert)). This press
release shall not constitute an offer to sell or the solicitation of an
offer to buy these securities, nor shall there be any sale of these
securities in any jurisdiction in which such offer, solicitation or sale
would be unlawful prior to the registration or qualification under the
securities laws of any such jurisdiction.
A preliminary prospectus supplement relating to the offering will be
filed with the SEC and will be available on the SEC's website located at www.sec.gov.
Copies of the preliminary prospectus supplement and accompanying
prospectus relating to these securities may be obtained, when available,
from Burrill LLC, One Embarcadero Center, Suie 2700, San Francisco, CA (News - Alert)
94111 or Maxim Group LLC, 405 Lexington Avenue, 2nd Floor, New York, NY
10174 or via telephone at (800) 724-0761. Before investing in the
offering, interested parties should read in their entirety the
prospectus supplement and the accompanying prospectus and the other
documents that Rexahn has filed with the SEC that are incorporated by
reference in the prospectus supplement and the accompanying prospectus,
which provide more information about Rexahn and the offering.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there be any
sale of these securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such jurisdiction.
About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals, Inc. is a clinical stage pharmaceutical company
dedicated to developing and commercializing first in class and market
leading therapeutics for cancer, CNS disorders, sexual dysfunction and
other unmet medical needs. Rexahn currently has three drug candidates in
Phase II clinical trials, Archexin®, Serdaxin®, and Zoraxel™ - all
potential best in class therapeutics - and a robust pipeline of
preclinical compounds to treat multiple cancers and CNS disorders.
Rexahn also operates key R&D programs of nano-medicines, 3D-GOLD, and
TIMES drug discovery platforms. For more information about Rexahn,
please visit www.rexahn.com.
To the extent any statements made in this press release deal with
information that is not historical, these are forward-looking statements
under the Private Securities Litigation Reform Act of 1995. Such
statements include, but are not limited to, statements about Rexahn's
plans, objectives, expectations and intentions with respect to future
operations and products and other statements identified by words such as
"will," "potential," "could," "can," "believe," "intends," "continue,"
"plans," "expects," "anticipates," "estimates," "may," other words of
similar meaning or the use of future dates. Forward-looking statements
by their nature address matters that are, to different degrees,
uncertain. Uncertainties and risks may cause Rexahn's actual results to
be materially different than those expressed in or implied by Rexahn's
forward-looking statements. For Rexahn, particular uncertainties and
risks include, among others, the difficulty of developing pharmaceutical
products, obtaining regulatory and other approvals and achieving market
acceptance; the marketing success of Rexahn's licensees or sublicensees;
the success of clinical testing; and Rexahn's need for and ability to
obtain additional financing. More detailed information on these and
additional factors that could affect Rexahn's actual results are
described in Rexahn's filings with the U.S. Securities and Exchange
Commission, including its most recent annual report on Form 10-K and
subsequent quarterly reports on Form 10-Q. All forward-looking
statements in this press release speak only as of the date of this press
release. Rexahn undertakes no obligation to update or revise any
forward-looking statement, whether as a result of new information,
future events or otherwise.
[ Back To Homepage ]